Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shield-TAF: TAF for Prevention of HBV MTCT
NCT05177926Phase 4Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Rate of mother-to-child transmission of HBV at 32 months. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05177926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177926.